Low IL-13Rα1 expression on mast cells tunes them unresponsive to IL-13 |
|
Author: | Salomaa, Tanja1,2,3; Kummola, Laura1; González-Rodríguez, Martín Ignacio1,2,3; |
Organizations: |
1Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland 2Fimlab Laboratories, 33520 Tampere, Finland 3Northern Finland Laboratory Centre (NordLab), 90220 Oulu, Finland
4Department of Orthopaedics and Traumatology, Tampere University Hospital, 33520 Tampere, Finland
5Research Unit of Biomedicine, University of Oulu, 90570 Oulu, Finland |
Format: | article |
Version: | published version |
Access: | open |
Online Access: | PDF Full Text (PDF, 0.9 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe20230918130277 |
Language: | English |
Published: |
Oxford University Press,
2023
|
Publish Date: | 2023-09-18 |
Description: |
AbstractCytokine-mediated mast cell regulation enables precise optimization of their own proinflammatory cytokine production. During allergic inflammation, interleukin (IL)-4 regulates mast cell functions, tissue homing, and proliferation, but the direct role of closely related IL-13 for mast cell activation remains unclear. Previous work has shown that mast cells are potent IL-13 producers, but here we show that mouse mast cells do not directly respond to IL-13 by Stat6 activation, as they do not express measurable amount of IL-13 receptor α1 (IL-4Rα1) messenger RNA. Consequently, IL-4 responses are mediated via type I IL-4R (IL-4/IL4Rα/γC), and IL-4–induced Stat6 activation is abolished in γC-deficient mast cells. Type II IL-4R deficiency (IL-13Rα1 knockout) has no effect on IL-4–induced Stat6 activation. In basophils, both IL-4 and IL-13 induce Stat6 activation in wild-type and γC-deficient cells, while in type II IL-4R–deficient basophils, IL-4 signaling is impaired at low ligand concentration. Thus, mast cell and basophil sensitivity to IL-4/IL-13 is different, and in mast cells, lack of IL-13Rα1 expression likely explains their unresponsiveness to IL-13. see all
|
Series: |
Journal of leukocyte biology |
ISSN: | 0741-5400 |
ISSN-E: | 1938-3673 |
ISSN-L: | 0741-5400 |
Volume: | 114 |
Issue: | 2 |
Pages: | 187 - 194 |
DOI: | 10.1093/jleuko/qiad065 |
OADOI: | https://oadoi.org/10.1093/jleuko/qiad065 |
Type of Publication: |
A1 Journal article – refereed |
Field of Science: |
3111 Biomedicine 1182 Biochemistry, cell and molecular biology |
Subjects: | |
Funding: |
This work was supported by the Academy of Finland (grants 25013080481 and 25013142041 [to I.S.J.] and grant 287907 [to T.A.H.J.]), the Competitive State Research Financing of the Expert Responsibility Area of Fimlab Laboratories (grant X51409 [to I.S.J.]), the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (grants 9X011 and 9V010 [to T.A.H.J.]), the Tampere University Hospital Support Foundation (to I.S.J. and T.A.H.J.), the Tampere Tuberculosis Foundation (to I.S.J. and T.A.H.J.), the Päivikki and Sakari Sohlberg Foundation (to T.A.H.J.), the Orion Research Foundation (to T.S.), Allergy Research Foundation (to T.S. and M.I.G.-R.), and Nordlab Laboratories (grant X3710-KT0011 [to I.S.J.]). |
Copyright information: |
© The Author(s) 2023. Published by Oxford University Press on behalf of Society for Leukocyte Biology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
https://creativecommons.org/licenses/by/4.0/ |